Bavarian Nordic IP Suit Over Cancer Vaccine Lives

Law360, New York (May 11, 2009, 12:00 AM EDT) -- A judge has rejected Oxford Biomedica PLC's effort to jettison Bavarian Nordic A/S' amended complaint in a patent infringement suit over Oxford Biomedica's experimental cancer vaccine TroVax.

Judge Michael M. Anello of the U.S. District Court for the Southern District of California ruled Friday that Bavarian Nordic may continue to pursue claims related to its rival’s TroVax treatment.

Largely funded by Sanofi-Aventis U.S. LLC, Oxford BioMedica has sought to develop TroVax, a cancer vaccine that incorporates Bavarian Nordic’s patented method of delivering recombinant vaccines, according to...
To view the full article, register now.